HIV-2EU—Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update: Table 1.-Reference-Cited by-同舟云学术

HIV-2EU—Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update: Table 1.

Published:2015-07-17 Issue:8 Volume:61 Page:1346-1347
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:Clin Infect Dis.

Author:

Charpentier Charlotte,Camacho Ricardo,Ruelle Jean,Eberle Josef,Gürtler Lutz,Pironti Alejandro,Stürmer Martin,Brun-Vézinet Françoise,Kaiser Rolf,Descamps Diane,Obermeier Martin

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/61/8/1346/1072351/civ572.pdf

Reference10 articles.

1. HIV-2EU: Supporting Standardized HIV-2 Drug Resistance Interpretation in Europe

2. Complex Patterns of Protease Inhibitor Resistance among Antiretroviral Treatment-Experienced HIV-2 Patients from Senegal: Implications for Second-Line Therapy

3. Genotypic resistance profiles of HIV-2-treated patients in West Africa

4. Mutations selected in HIV-2-infected patients failing a regimen including atazanavir

5. In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. British HIV Association guidelines for the management of HIV‐2 2021;HIV Medicine;2021-12

2. Human Immunodeficiency Virus Type 2: The Neglected Threat;Pathogens;2021-10-25

3. Short Communication: Update in Natural Antiretroviral Resistance-Associated Mutations Among HIV Type 2 Variants and Discrepancies Across HIV Type 2 Resistance Interpretation Tools;AIDS Research and Human Retroviruses;2021-10-01

4. Antiretroviral Therapy for HIV-2 Infection in Non-Endemic Regions;Aids Reviews;2021-03-24

5. Human Immunodeficiency Virus–2 (HIV-2): A Summary of the Present Standard of Care and Treatment Options for Individuals Living with HIV-2 in Western Europe;Clinical Infectious Diseases;2020-03-30